Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs

Table 5 A comparison of HTA and MCDA outcomes (economic criteria excluded) for 50 % threshold, multiple HTA restrictions imposed

		HTA
		Positive				Negative
		Unrestricted	Time restrictions	Limits to specific subpopulation	Finanacial restrictions	Clinical reasons	Economic reasons
MCDA	Positive	Cystadane, Volibris, Torisel, Glivec (DFSP), Glivec (GIST)	Zavesca, Kuvan, Increlex	Ventavis, Tracleer, Nexavar (HCC), Nplate, Tasigna, Glivec (MM), Yondelis	Zavesca, Tasigna, Yondelis	Elaprase, Fabrazyme, Somavert, Torisel	Fabrazyme, Somavert, Torisel, Nexavar (RCC)
MCDA	Negative	Vidaza, Glivec (ALL Ph+), Glivec (MDS/MPD), Revatio	None	Revlimid (MM/S), Sprycel, Atriance)	Revlimid (MM/S), Atriance	None	None

ISSN: 1750-1172